Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Retapamulin as a Decolonizing Agent for MRSA
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2017
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Retapamulin Microdialysis Feasibility Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2013
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Details : Undisclosed
Product Name : Altabax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2010
Lead Product(s) : Retapamulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Retapamulin
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2010
Lead Product(s) : Retapamulin
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable